Table 1 Baseline characteristics, management, and outcomes of pregnant women
Group A (N = 78) | Group B (N = 22) | Group C (N = 18) | P Value | |
|---|---|---|---|---|
Age, years | 28.4 ± 11.0 | 28.6 ± 9.7 | 27.5 ± 10.0 | 0.805 |
Nulliparous, n (%) | 32 (41.0) | 6 (27.3) | 2 (11.1) | 0.041 |
Diagnosis made | ||||
Before pregnancy, n (%) | 15 (19.2) | 5 (22.7) | 3 (16.7) | 0.886 |
During pregnancy, n (%) | 63 (80.8) | 17 (77.3) | 15 (83.3) | 0.886 |
NYHA class | ||||
I, n (%) | 68 (87.2) | 12 (54.5) | 0 (0.0) | < 0.001 |
II, n (%) | 8 (10.3) | 7 (31.8) | 8 (44.4) | 0.001 |
III, n (%) | 2 (2.6) | 2 (9.1) | 6 (33.3) | < 0.001 |
IV, n (%) | 0 (0.0) | 1 (4.5) | 4 (22.2) | < 0.001 |
Systolic PABP, mmHg | 45.3 ± 8.4 | 59.8 ± 12.2 | 87.6 ± 13.7 | < 0.001 |
NT-proBNP, pg/ml | 128.7 ± 54.3 | 196.6 ± 79.6 | 1723.5 ± 738.0 | < 0.001 |
LVEF, % | 65.4 ± 5.7 | 64.2 ± 14.8 | 61.9 ± 18.3 | 0.459 |
Management | ||||
Anticoagulation, n (%) | 0 (0.0) | 5 (22.7) | 7 (38.9) | < 0.001 |
Diuretic, n (%) | 0 (0.0) | 4 (18.2) | 9 (50.0) | < 0.001 |
Advanced drug, n (%) | 0 (0.0) | 3 (13.6) | 7 (38.9) | < 0.001 |
Pregnant Duration | ||||
Q ≤ 20 weeks, n (%) | 7 (8.9) | 2 (9.1) | 7 (38.9) | 0.035 |
20 < Q ≤ 30 weeks, n (%) | 2 (2.6) | 1 (4.6) | 3 (16.7) | 0.049 |
30 < Q ≤ 35 weeks, n (%) | 6 (7.7) | 7 (31.8) | 3 (16.7) | 0.013 |
Q > 35 weeks, n (%) | 63 (80.8) | 12 (54.5) | 5 (27.8) | < 0.001 |
Delivery model | ||||
Cesarean section, n (%) | 45 (63.4) | 19 (95.0) | 10 (90.9) | 0.039 |
Vaginal delivery, n (%) | 26 (36.6) | 1 (5.0) | 1 (10.1) | 0.003 |
Anesthesia | ||||
No, n (%) | 26 (33.3) | 1 (22.7) | 1 (5.56) | 0.003 |
Epidural anesthesia, n (%) | 43 (51.3) | 12 (50.0) | 10 (55.6) | 0.999 |
General anesthesia, n (%) | 19 (24.4) | 9 (40.9) | 7 (38.9) | 0.210 |
Maternal death, n (%) | 0 (0.00) | 1 (4.55) | 5 (27.8) | < 0.001 |